In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Dallas and Phoenix labs. The ability to test healthcare partner samples at any one of the three labs is a critical element in creating the reliability the CTS healthcare partners desire so they can provide the blood that saves patients’ lives.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...